CA2311119A1 - Method for transporting a molecular substance in predetermined areas of eucaryotic cells - Google Patents
Method for transporting a molecular substance in predetermined areas of eucaryotic cells Download PDFInfo
- Publication number
- CA2311119A1 CA2311119A1 CA002311119A CA2311119A CA2311119A1 CA 2311119 A1 CA2311119 A1 CA 2311119A1 CA 002311119 A CA002311119 A CA 002311119A CA 2311119 A CA2311119 A CA 2311119A CA 2311119 A1 CA2311119 A1 CA 2311119A1
- Authority
- CA
- Canada
- Prior art keywords
- molecular substance
- vehicle according
- protein
- pentamer
- viral protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000126 substance Substances 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 34
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 24
- 108091034117 Oligonucleotide Proteins 0.000 claims description 23
- 210000003855 cell nucleus Anatomy 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 210000000234 capsid Anatomy 0.000 claims description 13
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 11
- 238000010168 coupling process Methods 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- 238000002649 immunization Methods 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 6
- 108010017842 Telomerase Proteins 0.000 claims description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 5
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- QEQAPQHGLVGWMO-UHFFFAOYSA-N 2-hydroxy-4-[(2-iodoacetyl)amino]benzoic acid Chemical group OC(=O)C1=CC=C(NC(=O)CI)C=C1O QEQAPQHGLVGWMO-UHFFFAOYSA-N 0.000 claims description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 241001505332 Polyomavirus sp. Species 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000000921 morphogenic effect Effects 0.000 claims description 3
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 claims description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 108010052780 polyasparagine Proteins 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 description 10
- 238000001000 micrograph Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JIUYRPFQJJRSJB-QWRGUYRKSA-N His-His-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(O)=O)C1=CN=CN1 JIUYRPFQJJRSJB-QWRGUYRKSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DSWOTZCVCBEPOU-IUCAKERBSA-N Met-Arg-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCNC(N)=N DSWOTZCVCBEPOU-IUCAKERBSA-N 0.000 description 1
- IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
- DJACUBDEDBZKLQ-KBIXCLLPSA-N Ser-Ile-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O DJACUBDEDBZKLQ-KBIXCLLPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19829005.5 | 1998-06-29 | ||
| DE19829005A DE19829005C2 (de) | 1998-06-29 | 1998-06-29 | Verfahren zum Transport molekularer Substanz in vorgegebene Bereiche eukaryontischer Zellen |
| PCT/DE1999/001805 WO2000000224A2 (de) | 1998-06-29 | 1999-06-19 | Verfahren zum transport molekularer substanz in vorgegebene bereiche eukaryontischer zellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2311119A1 true CA2311119A1 (en) | 2000-01-06 |
Family
ID=7872407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002311119A Abandoned CA2311119A1 (en) | 1998-06-29 | 1999-06-19 | Method for transporting a molecular substance in predetermined areas of eucaryotic cells |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1007107A2 (de) |
| CA (1) | CA2311119A1 (de) |
| DE (1) | DE19829005C2 (de) |
| WO (1) | WO2000000224A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19952957B4 (de) * | 1999-11-03 | 2006-08-31 | Acgt Progenomics Ag | Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1319101C (en) * | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
| US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
| WO1992013568A1 (en) * | 1991-02-04 | 1992-08-20 | University Of Saskatchewan | Vp6 encapsulated drug delivery |
| DE4335025A1 (de) * | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
| JPH11506722A (ja) * | 1995-06-07 | 1999-06-15 | ベイラー・カレッジ・オブ・メディスン | 細胞に核酸を送達するための核酸運搬体 |
| GB9607899D0 (en) * | 1996-04-17 | 1996-06-19 | Scottish Crop Research Inst | Virus-like particle |
| DE19618797C2 (de) * | 1996-05-10 | 2000-03-23 | Bertling Wolf | Vehikel zum Transport molekularer Substanz |
| DE19750354A1 (de) * | 1997-11-13 | 1999-05-27 | November Ag Molekulare Medizin | Verfahren zur Applikation von Wirkstoffen |
-
1998
- 1998-06-29 DE DE19829005A patent/DE19829005C2/de not_active Expired - Fee Related
-
1999
- 1999-06-19 EP EP99939916A patent/EP1007107A2/de not_active Withdrawn
- 1999-06-19 CA CA002311119A patent/CA2311119A1/en not_active Abandoned
- 1999-06-19 WO PCT/DE1999/001805 patent/WO2000000224A2/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000000224A2 (de) | 2000-01-06 |
| EP1007107A2 (de) | 2000-06-14 |
| WO2000000224A3 (de) | 2000-04-13 |
| DE19829005C2 (de) | 2000-08-31 |
| DE19829005A1 (de) | 1999-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1700911B1 (de) | Methode zur in vitro Auseinander- und Wiederzusammensetzung von Papillomavirus virus-ähnlichen Teilchen (VLPs) | |
| KR0178022B1 (ko) | 단백질-다가양이온 결합체 | |
| Georgens et al. | Recombinant virus like particles as drug delivery system | |
| JPH10506796A (ja) | パピローマウイルス様キメラ粒子 | |
| JP2006257088A (ja) | ポリヌクレオチド送達のための組成物および方法 | |
| US12234260B2 (en) | Virus-like nanoparticles for oral delivery | |
| US7279306B2 (en) | Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof | |
| US20040152181A1 (en) | In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents | |
| Günther et al. | Protein and peptide delivery via engineered polyomavirus‐like particles | |
| US6380364B1 (en) | Chimeric biotin-binding papillomavirus protein | |
| JP2003061693A (ja) | ウイルス様粒子、その製造方法およびその使用 | |
| JP2000500020A (ja) | 正十二面体様アデノウイルス・タンパク質複合体、それを含む組成物、及びその使用方法 | |
| JP3733329B2 (ja) | 分子性物質のためのモジュール式輸送系ならびにその製造方法および使用方法 | |
| JPS61500971A (ja) | Ｂ型肝炎ウイルスの表面抗原と重合ヒト血清アルブミンレセプタ−とを有する粒子を含むワクチン製造に有用な組成物、前記の如き粒子を産生し得る動物細胞、並びにこれら細胞を得るための方法 | |
| AU8284298A (en) | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy | |
| Suchanová et al. | Applications of viral nanoparticles based on polyomavirus and papillomavirus structures | |
| EP1250593B1 (de) | In-vitro-methode zur zerlegung und zum wiederzusammenfügen von papillomavirusartigen partikeln | |
| US6962777B1 (en) | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents | |
| JP2002500637A (ja) | 遺伝物質のデリバリー用パポバウイルスカプシド蛋白質の使用 | |
| EP0969013B1 (de) | Peptide zur Inhibition von HPV E7 Proteinen | |
| HUP0200679A2 (en) | Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients | |
| Žáčková Suchanová | Targeting of viral nanoparticles to cancer specific receptors | |
| Cao et al. | Antibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C–Staphylococcus A protein | |
| US20030096259A1 (en) | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents | |
| JP2003513628A (ja) | タンパク質シェルにおける分子性物質の定方向パッケージング方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |